Alain Madgin

Significant uncertainty surrounds drug reimbursement in Quebec, as the healthcare system undergoes major reform. This session will provide a high-level overview of the current landscape, including:

• INESSS under pressure: Budget constraints and the challenge of keeping pace with the Canada Drug Agency.
• Limitations of the public drug plan: Inability to cover numerous new treatments for rare diseases, including upcoming cell and gene therapies.
• System reform and Santé Québec: The creation of Santé Québec reshapes operational responsibilities — with major implications for group purchasing, hospital pharmacies, and service delivery.

Explore the key challenges for market access in Quebec and open the floor for your questions.